期刊文献+

原发性胆汁性肝硬化无创性肝纤维化诊断模型的建立 被引量:3

A noninvasive diagnostic model of liver fibrosis using serum markers in primary biliary cirrhosis
原文传递
导出
摘要 目的采用常规实验室指标建立原发性胆汁性肝硬化(PBC)无创性肝纤维化诊断模型,验证并评判其诊断价值。方法收集2003年1月-2011年6月于首都医科大学附属北京友谊医院经肝活检确诊为PBC的患者73例,将其常规实验室指标与组织学分期进行相关性分析和logistic回归分析,创建肝纤维化诊断模型。结果建立了一个由血小板计数、血清胆碱酯酶、白蛋白、HDL.C和凝血酶原活动度5个常规指标组成的预测模型——H指数,其判断进展期纤维化(Ⅲ-Ⅳ期)的AUCROC为0.861,H指数〈-2.20预测早期纤维化(Ⅰ-Ⅱ期)的敏感性为96.6%,H指数〉0.41预测存在进展期纤维化的特异性为93.2%。结论本研究由常规实验室指标建立的肝纤维化无创诊断模型能协助准确区分PBC患者的早期(Ⅰ~Ⅱ期)和进展期(Ⅲ一Ⅳ期)病变。 Objective To verify and assess diagnostic value of noninvasive diagnostic model of liver fibrosis in primary biliary cirrhosis (PBC) based on conventional laboratory markers. Methods Seventy- three patients with PBC diagnosed by liver biopsy between January 2003 and June 2011 in Beijing Friendship Hospital, Capital Medical University were recruited in this study. Correlation analysis and logistic regression analysis between the conventional laboratory markers and histology stages were assessed. A liver fibrosis diagnostic model was established based upon aforementioned biomarkers and verified by its sensitivity and specificity for predicting the liver fibrosis. Results The predictive model (H index) consisting of five conventional laboratory markers, i.e., platelet count, serum cholinesterase, albumin, HDL-C and prothrombin time activity, could predict advanced fibrosis ( stagesⅢ-Ⅳ) with an AUCaoc of 0. 861. The sensitivity of predicting the absence of advanced fibrosis using H index 〈 - 2. 20 was 96. 6% and the specificity of predicting the presence of advanced fibrosis using H index 〉 0. 41 was 93.2%. Conclusion The established noninvasive diagnostic model consisting of five laboratory markers could accurately distinguish pathological changes of early stage PBC ( stages Ⅰ -Ⅱ) from advanced stage PBC ( stages m-iv).
出处 《中华内科杂志》 CAS CSCD 北大核心 2012年第8期618-622,共5页 Chinese Journal of Internal Medicine
基金 北京市科技新星培养计划(2006854)
关键词 肝硬化 胆汁性 无创诊断 模型 肝纤维化 Liver cirrhosis,biliary Noninvasive diagnosis Model Liver fibrosis
  • 相关文献

参考文献17

  • 1Martínez SM, Crespo G, Navasa M, et al.Noninvasive assessment of liver fibrosis.Hepatology,2011,53:325-335.
  • 2Imbert-Bismut F, Ratziu V, Pieroni L, et al.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet,2001,357:1069-1075.
  • 3Rosenberg WM, Voelker M, Thiel R, et al.Serum markers detect the presence of liver fibrosis: a cohort study.Gastroenterology,2004,127:1704-1713.
  • 4Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.BMC Gastroenterol, 2010,10:103.
  • 5刘卫平,许德军,赵连荣,陆忠华,王玉华,郎振为,王贵强.慢性乙型肝炎肝纤维化无创检测模型建立及应用价值验证[J].中华内科杂志,2008,47(4):308-312. 被引量:18
  • 6Su CW, Chan CC, Hung HH, et al.Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis.J Clin Gastroenterol,2009,43:876-883.
  • 7Corpechot C, Poujol-Robert A, Wendum D, et al.Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.Liver Int,2004,24:187-193.
  • 8Frkkil M, Rautiainen H, Krkkinen P, et al.Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.Liver Int,2008,28:787-797.
  • 9Lindor KD, Gershwin ME, Poupon R, et al.Primary biliary cirrhosis.Hepatology, 2009,50:291-308.
  • 10Forns X, Ampurdanès S, Llovet JM, et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.Hepatology,2002,36(4 Pt 1):986-992.

二级参考文献12

  • 1无.慢性乙型肝炎防治指南[J].实用肝脏病杂志,2006,9(1):8-18. 被引量:825
  • 2张文胜,王宝恩,王泰龄,欧晓娟,陈煜,李琴,王小明,钱林学,马红,贾继东.慢性乙型肝炎肝纤维化无创性诊断模型的建立[J].中华肝脏病杂志,2006,14(3):169-173. 被引量:81
  • 3Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol, 2002, 97: 2614-2618.
  • 4Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 2002, 36(4 Pt 1 ) : 986-992.
  • 5Wai CT, Greenson JK, Fontana R J, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 2003, 38:518-526.
  • 6Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 2001, 357 : 1069-1075.
  • 7Blanc JF, Bioulac-Sage P, Balabaud C, et al. Investigation of liver fibrosis in clinical practice. Hepatol Res, 2005, 32: 1-8.
  • 8Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol, 2003, 39: 222-230.
  • 9Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology, 2005, 42: 1437-1445.
  • 10Bacq Y, Schillio Y, Brechot JF, et al. Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol, 1993,17: 364-369.

共引文献17

同被引文献19

  • 1Martinez SM, Crespo G, Navasa M, et al. Noninvasive assessment of liver fibrosis. Hepatology, 2011, 53. 325-335.
  • 2Su CW, Chan CC, Hung HH, et al. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterul, 2009, 43:876 -883.
  • 3Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 2002, 36: 986-992.
  • 4Wai CH, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patient with chronic hepatitis C. Hepatology, 2003, 38: 518 -526.
  • 5Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology, 2005, 42: 282-292.
  • 6Taefi A, Huang CC, Kolli K, et al. Red cell distribution width to platlet ratio, a useful indicater of liver fibrosis in chronic hepatitis patients. Hepatol Int, 2015, 9:454-460.
  • 7Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology, 2009, 50: 291-308.
  • 8Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patient with HIV/HCV coinfection. Hepat61ogy, 2006, 43:1317 -1325.
  • 9Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4.- an inexpensive and accurate marker of fibrosis in HCV infection, comparison with liver biopsy and fibrotest. Hepatology, 2007, 46: 32-36.
  • 10Lammers WJ, Hirschfield GM, Corpechot C, et aL Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149 : 1804-1812, e4.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部